Literature DB >> 22231490

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.

M Braun1, D Goltz, D Adler, W Vogel, D Böhm, V Scheble, K Sotlar, F Fend, S-H Tan, A Dobi, G Kristiansen, N Wernert, S Perner.   

Abstract

BACKGROUND: Overexpression of the ERG protein is highly prevalent in prostate cancer (PCa) and commonly results from gene fusions involving the ERG gene. Recently, N-terminal epitope-targeted mouse and a C-terminal epitope-targeted rabbit monoclonal anti-ERG antibody (ERG-MAbs) have been introduced for the detection of the ERG protein. Independent studies reported that immunohistochemistry (IHC) with both ERG-MAbs highly correlates with the underlying ERG gene rearrangement status. However, comparative studies of both antibodies are lacking. Here, we are among the first to compare the mouse ERG-MAb with the rabbit ERG-MAb for their concordance on the same PCa cohort. Furthermore, we assessed whether the ERG protein expression is conserved in lymph node and distant PCa metastases.
METHODS: We evaluated tissue microarrays of 278 specimens containing 265 localized PCa, 29 lymph node, 30 distant metastases and 13 normal prostatic tissues. We correlated ERG protein expression with ERG rearrangement status using an ERG break-apart fluorescence in-situ hybridization assay and IHC of both ERG-MAbs.
RESULTS: ERG expression and ERG rearrangement status were highly concordant regardless of whether the mouse or rabbit ERG-MAb was used (97.8% versus 98.6%, respectively). Of interest, both ERG antibodies reliably detected the ERG expression in lymph node and distant PCa metastases, of which a subset underwent decalcification. Lymphocytes only revealed immunoreactivity using the rabbit ERG-MAb. If ERG protein expression was present in localized PCa, we observed the same pattern in the corresponding lymph node metastases.
CONCLUSIONS: By demonstrating a broad applicability of IHC to study ERG protein expression using either antibody, this study adds an important step toward a facilitated routine clinical application. Further, we demonstrate that the clonal nature of the ERG rearrangement is not restricted to the genomic level, but proceeds in the proteome. Together, our results simplify future efforts to further eliucidate the biological role of ERG in PCa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22231490     DOI: 10.1038/pcan.2011.67

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  37 in total

1.  SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.

Authors:  Kuo-Cheng Huang; Andrew Evans; Bryan Donnelly; Tarek A Bismar
Journal:  Pathol Oncol Res       Date:  2016-10-13       Impact factor: 3.201

2.  Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.

Authors:  Diane Goltz; Heidrun Gevensleben; Jörn Dietrich; Jörg Ellinger; Jennifer Landsberg; Glen Kristiansen; Dimo Dietrich
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

Review 3.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

4.  Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer.

Authors:  Angela Queisser; Susanne A Hagedorn; Martin Braun; Wenzel Vogel; Stefan Duensing; Sven Perner
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

5.  Predominance of ERG-negative high-grade prostate cancers in African American men.

Authors:  James Farrell; Denise Young; Yongmei Chen; Jennifer Cullen; Inger L Rosner; Jacob Kagan; Sudhir Srivastava; David G McLEOD; Isabell A Sesterhenn; Shiv Srivastava; Gyorgy Petrovics
Journal:  Mol Clin Oncol       Date:  2014-08-07

6.  ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Authors:  K-C Huang; M Dolph; B Donnelly; T A Bismar
Journal:  Clin Transl Oncol       Date:  2014-05-06       Impact factor: 3.405

7.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

8.  TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Authors:  Anuradha Gopalan; Margaret A Leversha; Maria E Dudas; Alexandra C Maschino; Jeremy Chang; Hikmat A Al-Ahmadie; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; Samson W Fine
Journal:  Histopathology       Date:  2013-05-23       Impact factor: 5.087

9.  Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.

Authors:  E Sophie Spencer; Richard B Johnston; Ryan R Gordon; Jared M Lucas; Cigdem Himmetoglu Ussakli; Antonio Hurtado-Coll; Shiv Srivastava; Peter S Nelson; Christopher R Porter
Journal:  Prostate       Date:  2013-01-17       Impact factor: 4.104

10.  Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Authors:  A Queisser; S Hagedorn; H Wang; T Schaefer; M Konantz; S Alavi; M Deng; W Vogel; A von Mässenhausen; G Kristiansen; S Duensing; J Kirfel; C Lengerke; S Perner
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.